Article
Biochemistry & Molecular Biology
Francesca Sanguedolce, Ugo Giovanni Falagario, Magda Zanelli, Andrea Palicelli, Maurizio Zizzo, Stefano Ascani, Simona Tortorella, Vito Mancini, Angelo Cormio, Giuseppe Carrieri, Luigi Cormio
Summary: Molecular subtyping of bladder cancer using immunohistochemical markers can help stratify patient risk. This study investigated the correlation between molecular subtypes and conventional prognostic variables in muscle-invasive bladder cancer and found a significant association between the pattern of muscularis propria invasion and molecular subtypes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biotechnology & Applied Microbiology
Yongqing Zhang, Qingyuan Chen, Meiqin Gong, Yuanqi Zeng, Dongrui Gao
Summary: This study proposes constructing gene regulatory networks under different molecular subtypes of MIBC and analyzing the regulatory differences. Differential expression analysis and network analysis revealed significant differences in expression and regulatory relationships of genes such as SERPINI1, NOTUM, and FGFR1. Pathway enrichment analysis showed pathways like Neuroactive ligand-receptor interaction and Cytokine-cytokine receptor interaction are significantly enriched with diverse genes in bladder cancer subtypes.
Article
Cell Biology
Florus C. de Jong, Teemu D. Laajala, Robert F. Hoedemaeker, Kimberley R. Jordan, Angelique C. J. van der Made, Egbert R. Boeve, Deric K. E. van der Schoot, Bart Nieuwkamer, Emiel A. M. Janssen, Tokameh Mahmoudi, Joost L. Boormans, Dan Theodorescu, James C. Costello, Tahlita C. M. Zuiverloon
Summary: The recommended treatment for high-risk non-muscle-invasive bladder cancer patients is tumor resection followed by adjuvant Bacillus Calmette-Guerin (BCG) bladder instillations. However, only 50% of patients benefit from this therapy. Identifying tumors unlikely to respond to BCG can lead to alternative treatments for these patients.
SCIENCE TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Ahmad Almarzouq, Ronald Kool, Yarab Al Bulushi, Gautier Marcq, Luis Souhami, Fabio L. Cury, Fadi Brimo, Jaron Chong, Wassim Kassouf
Summary: This study investigated the incidence of sarcopenia and its impact on oncological outcomes in MIBC patients treated with trimodal therapy. The results showed that sarcopenia status was not independently associated with either complete response to TMT or overall survival.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Review
Andrology
Xinxiang Fan, Wang He, Jian Huang
Summary: In recent years, less-invasive bladder-sparing trimodal therapy (TMT) has been increasingly used for selected patients with muscle-invasive bladder cancer (MIBC) who are unfit for or decline radical cystectomy (RC). This review summarizes the current evidence and future perspectives of bladder-sparing therapy for MIBC. TMT is a well-tolerated and curative alternative to RC for selected patients with localized MIBC, and the emergence of immunotherapy may further improve its effectiveness.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Review
Andrology
Xinxiang Fan, Wang He, Jian Huang
Summary: In recent years, the use of less-invasive bladder-sparing trimodal therapy (TMT) for selected patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) has been increasing. This review summarizes the current evidence and future perspectives of bladder-sparing therapy for MIBC. Combination therapy is more effective than monotherapy, and radiotherapy alone has poorer outcomes compared to chemoradiotherapy. Appropriate patient selection and a multi-disciplinary approach are crucial for successful bladder-sparing therapy.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2023)
Article
Multidisciplinary Sciences
A. Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A. McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro A. A. Castro, Clarice S. Groeneveld, Aurelien de Reynies, Vadim I. Nazarov, Vasily O. Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J. Meeks
Summary: Checkpoint immunotherapy (CPI) has shown efficacy in some advanced-stage bladder cancer patients, but not all. By analyzing tumor and immune microenvironment in pre- and post-treatment tumors, researchers identified genetic and transcriptomic programs associated with response or resistance to CPI. They also discovered that inhibiting the histone demethylase KDM5B enhances immunogenicity in certain subtypes of bladder cancer.
NATURE COMMUNICATIONS
(2023)
Article
Multidisciplinary Sciences
Won Sik Ham, Jee Soo Park, Won Sik Jang, Young Deuk Choi, Jongchan Kim
Summary: The study suggests a correlation between larger prostate volume and worse recurrence and progression-free survival in non-muscle invasive bladder cancer.
SCIENTIFIC REPORTS
(2021)
Review
Andrology
Hiroshi Fukushima, Fumitaka Koga
Summary: According to our literature review, sarcopenia does not affect the responses to trimodal therapy and prognosis in MIBC patients treated with bladder preservation therapy. Although the effect of sarcopenia on complication rates of bladder preservation therapy is inconclusive due to limited evidence, bladder preservation therapy could be a viable alternative option in carefully selected MIBC patients regardless of the presence of sarcopenia.
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2022)
Article
Oncology
Sara Soltanzadeh, Arefeh Saeedian, Reza Ghalehtaki, Mohsen Ayati, Mohammadreza Nowroozi, Peiman Haddad, Mahdieh Shafiee Sabet, Amin Kheirolahi
Summary: This study evaluated the feasibility, tolerance, and efficacy of concurrent chemoradiotherapy using cisplatin and capecitabine in patients with muscle-invasive bladder cancer. The results showed good tolerability and promising efficacy. Further studies are warranted to investigate the use of this combination in the treatment of bladder cancer.
CLINICAL GENITOURINARY CANCER
(2023)
Review
Oncology
Hannah Slovacek, Jerry Zhuo, Jennifer M. Taylor
Summary: NMIBC is a heterogeneous malignancy with high recurrence and progression rates, necessitating uniform recommendations for diagnosis and management. Guidelines worldwide have adopted risk-stratification at diagnosis to provide evidence-based treatment and surveillance recommendations. Improved endoscopic technologies enhance NMIBC detection and decrease recurrence.
CURRENT ONCOLOGY REPORTS
(2021)
Article
Oncology
Leslie Ballas, Parminder Singh, Seth P. Lerner
Summary: Radical cystectomy with bilateral pelvic lymphadenectomy and trimodality bladder-sparing therapy are both effective treatment options for patients with nonmetastatic muscle invasive bladder cancer. Multidisciplinary evaluation and unbiased discussion should be provided to eligible patients. The barriers to broader acceptance and utilization of trimodality bladder-sparing therapy are discussed, and support for clinical trials is encouraged.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Biochemistry & Molecular Biology
Tanan Bejrananda, Jirakrit Saetang, Surasak Sangkhathat
Summary: This study identified three novel molecular subtypes of muscle invasive bladder cancer (MIBC), designated as clusters A, B, and C. The differential gene expression patterns of these subtypes were associated with clinical outcomes and response to chemotherapy. Cluster B showed the best overall survival and a better response to neoadjuvant chemotherapy.
Article
Oncology
Nikhil V. Kotha, Abhishek Kumar, Tyler J. Nelson, Edmund M. Qiao, Alex S. Qian, Rohith S. Voora, Rana R. Mckay, Brent S. Rose, Tyler F. Stewart
Summary: This study suggests that a short-term delay in definitive therapy may not affect long-term outcomes for patients with MIBC undergoing CRT. It provides information to aid patients and clinicians navigate the unique challenges of MIBC care in both pandemic and non-pandemic times.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Review
Biochemistry & Molecular Biology
Francesco Claps, Nicola Pavan, Luca Ongaro, Domenico Tierno, Gabriele Grassi, Carlo Trombetta, Gabriele Tulone, Alchiede Simonato, Riccardo Bartoletti, Laura S. Mertens, Bas W. G. van Rhijn, Maria Carmen Mir, Bruna Scaggiante
Summary: Urothelial carcinoma is a common type of cancer, with bladder carcinoma being the most prevalent form. For non-muscle-invasive bladder cancer that does not respond to BCG treatment, radical cystectomy is currently the standard treatment. However, this surgery carries high risks and impacts the patient's quality of life, highlighting the need for alternative bladder-preserving therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Letter
Urology & Nephrology
Soichiro Yoshida, Hisashi Matsushima, Yasuhisa Fujii
WORLD JOURNAL OF UROLOGY
(2022)
Article
Oncology
Soichiro Yoshida, Taro Takahara, Yuki Arita, Kazuma Toda, Koichiro Kimura, Hajime Tanaka, Minato Yokoyama, Yoh Matsuoka, Ryoichi Yoshimura, Yasuhisa Fujii
Summary: Progressive site-directed therapy (PSDT) may improve the efficacy of subsequent treatment for oligometastatic castration-resistant prostate cancer and prolong overall survival.
Article
Urology & Nephrology
Toshitaka Uematsu, Toshiki Kijima, Atsuko Takada-Owada, Daisaku Nishihara, Kazuyuki Ishida, Takao Kamai
Summary: The application of ICIs in elderly patients is challenging due to the lack of safety and efficacy data. However, this study shows that older patients may not necessarily be excluded from ICI therapy.
UROLOGY CASE REPORTS
(2022)
Article
Urology & Nephrology
Wei Chen, Minato Yokoyama, Masaki Kobayashi, Bo Fan, Shohei Fukuda, Yuma Waseda, Hajime Tanaka, Soichiro Yoshida, Masumi Ai, Kiyohide Fushimi, Norio Nonomura, Yasuhisa Fujii
Summary: This study explored the trends in radical cystectomy and compared surgical outcomes among different approaches, with a focus on robot-assisted radical cystectomy. The results showed an increasing number of minimally invasive procedures over the past decade, with satisfactory surgical outcomes, except for a longer anesthesia time.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Editorial Material
Urology & Nephrology
Toshiki Kijima
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Yuki Nakamura, Hiroshi Fukushima, Kasumi Yoshitomi, Takahiko Soma, Masaki Kobayashi, Bo Fan, Motohiro Fujiwara, Yudai Ishikawa, Shohei Fukuda, Yuma Waseda, Hajime Tanaka, Soichiro Yoshida, Minato Yokoyama, Yasuhisa Fujii
Summary: This study assessed the prognostic significance of the detailed bladder neck involvement (BNI) location in non-muscle-invasive bladder cancer (NMIBC) patients. Dorsal bladder neck involvement was found to be an independent risk factor for progression in primary NMIBC. A simple and practical prognostic model, including the BNI location, was developed to assist in selecting the optimal treatment and timing.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Medicine, General & Internal
Chiina Hata, Yuki Fukawa, Toru Motoi, Yuko Kinowaki, Takumi Akashi, Kenichi Ohashi, Yudai Ishikawa, Yuma Waseda, Yasuhisa Fujii, Ryota Kakuta, Sadakatsu Ikeda, Iichiroh Onishi
Summary: This report presents a case of a 77-year-old Japanese male with primary giant cell tumor of soft tissue (GCTST) of the kidney, which showed peritoneal dissemination and malignant transformation. The histological and immunohistochemical characteristics of the tumors were analyzed, suggesting they were sequential. This rare case provides insights into the genetic mutations and disease concepts of GCTST.
Article
Nutrition & Dietetics
Shugo Yajima, Hiroshi Fukushima, Shioto Oda, Rikuto Yasujima, Kohei Hirose, Naoya Okubo, Yosuke Umino, Madoka Kataoka, Yasukazu Nakanishi, Fumitaka Koga, Hitoshi Masuda
Summary: This study aimed to investigate the role of the SARC-F questionnaire as a screening tool for elderly patients undergoing elective major surgery for urologic cancer and to evaluate its correlation with indicators of sarcopenia. The study found that SARC-F scores were associated with postoperative ambulation failure and overall survival, suggesting that it can be used to identify elderly patients at a higher risk of unfavorable outcomes after surgery.
CLINICAL NUTRITION
(2023)
Article
Oncology
Fumitaka Koga
Summary: This article reviews the use of selective bladder-sparing therapy for muscle-invasive bladder cancer and compares its oncological outcomes with radical cystectomy. It also discusses predictive biomarkers for treatment decision-making and a novel strategy to boost the immune response in bladder-sparing therapy.
EXPERT REVIEW OF ANTICANCER THERAPY
(2023)
Article
Urology & Nephrology
Bo Fan, Minato Yokoyama, Masaki Kobayashi, Yuki Nakamura, Motohiro Fujiwara, Yudai Ishikawa, Shohei Fukuda, Yuma Waseda, Hajime Tanaka, Soichiro Yoshida, Yasuhisa Fujii
Summary: This study aimed to evaluate the incidence and risk factors of a 20% decrease in eGFR after RN and PN, as well as the difference in the incidence of ESRD with or without the decrease. The results showed that diabetes mellitus, proteinuria, and perioperative complications were independent risk factors for the 20% decrease in eGFR. The incidence of ESRD after the decrease was as high as 24.5% at 6 years.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Ichiro Yonese, Masaya Ito, Yuma Waseda, Shuichiro Kobayashi, Masahiro Toide, Ryoji Takazawa, Fumitaka Koga
Summary: This study aimed to investigate whether even a minimally invasive diagnostic procedure like ureteral catheterization (UCath) could significantly increase the risk of intravesical recurrence (IVR) in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). A retrospective study enrolled 163 patients undergoing RNU for UTUC between 2010 and 2021. The results showed that UCath was significantly associated with IVR and shorter IVR-free survival (IVRFS) in UTUC patients.
WORLD JOURNAL OF UROLOGY
(2023)
Article
Oncology
Toshiki Kijima, Shohei Fukuda, Hiroshi Fukushima, Sho Uehara, Yosuke Yasuda, Soichiro Yoshida, Minato Yokoyama, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii
Summary: This study assessed the long-term outcomes for patients with recurrent adrenocortical carcinoma after multimodal salvage therapy and found that long-term disease control and survival could be achieved in highly selected patients using a multidisciplinary approach. Salvage surgery may be considered in patients with limited recurrent sites and positive response to chemotherapy/chemoradiotherapy.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Urology & Nephrology
Daisaku Nishihara, Toshiki Kijima, Kyoko Arai, Takao Kamai
Summary: This study investigated the expression of HHLA2 and FAP in UTUC tissues and found that increased expression of HHLA2 in tumor cells was associated with a favorable clinical profile, while increased expression of HHLA2 in stromal cells was associated with a higher histological grade. Furthermore, positive expression of FAP in stromal cells was significantly associated with higher histological grade, advanced disease stage, and lymphovascular invasion. Higher expression of t-HHLA2 was associated with better survival outcomes, while positive expression of s-FAP was associated with shorter progression-free survival.
INTERNATIONAL UROLOGY AND NEPHROLOGY
(2023)
Article
Urology & Nephrology
Madoka Kataoka, Minato Yokoyama, Yuma Waseda, Masaya Ito, Masaki Kobayashi, Motohiro Fujiwara, Yuki Nakamura, Yudai Ishikawa, Shohei Fukuda, Hajime Tanaka, Soichiro Yoshida, Hitoshi Masuda, Yasuhisa Fujii
Summary: This study aimed to evaluate longitudinal changes in lower urinary tract symptoms (LUTS) after artificial urinary sphincter (AUS) implantation in patients undergoing radiation therapy (RT) compared to those in non-irradiated patients. The results showed that LUTS in patients with a history of pelvic RT deteriorated gradually after AUS implantation, while there was no significant change in LUTS in patients without a history of pelvic RT.
LUTS-LOWER URINARY TRACT SYMPTOMS
(2024)
Article
Urology & Nephrology
Yudai Ishikawa, Hajime Tanaka, Motohiro Fujiwara, Yuki Nakamura, Shohei Fukuda, Yuma Waseda, Soichiro Yoshida, Minato Yokoyama, Yasuhisa Fujii
Summary: The objective of this study was to analyze the incidence and risk factors of intraoperative hypotension related to photodynamic diagnosis-assisted transurethral resection of bladder tumor (PDD-TURBT) with oral 5-aminolevulinic acid (5-ALA). The results showed that intraoperative hypotension occurred more frequently in patients who underwent PDD-TURBT than in those who underwent conventional TURBT. The use of oral 5-ALA decreased preoperative blood pressure elevation and may be responsible for intraoperative hypotension.
INTERNATIONAL JOURNAL OF UROLOGY
(2023)